1 Min Read
Nov 8 (Reuters) - Kerrisdale Capital:
* Kerrisdale Capital reveals short position in Prothena Corp, says Prothena’s “lead asset, NEOD001, will fail its ongoing phase 2B and phase 3 trials” Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.